Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation

Samira Reyes Dassum, Ryan Ferguson, Patricia Woods, Maura Flynn, Karen Visnaw, Erika Holmberg, Sara Schiller, Colleen Shannon, Mary Brophy, Paul Monach, Sarah Leatherman, Westyn Branch-Elliman, VISN-1 Clinical Trials Network COVID-19 Investigators, Samira Reyes Dassum, Ryan Ferguson, Patricia Woods, Maura Flynn, Karen Visnaw, Erika Holmberg, Sara Schiller, Colleen Shannon, Mary Brophy, Paul Monach, Sarah Leatherman, Westyn Branch-Elliman, VISN-1 Clinical Trials Network COVID-19 Investigators

Abstract

Background: Early in the pandemic, there were no evidence-based treatments for SARS-CoV-2, creating an urgent need to identify effective therapeutics. However, public participation in medical research is low; trial enrollment in the US is typically 10-20%. Thus, the aim of this study was to identify common themes underpinning patient reasons to decline participation and evaluate the impact of specific contextual factors.

Methods: This sub-study was conducted in five VISN-1 Clinical Trials Network participating facilities from 4/10/2020-2/3/2021. The trial evaluated the addition of the IL-6-inhibitor, Sarilumab, to the current standard of care for inpatients with moderate-to-severe SARS-CoV-2. Consent procedures varied by site and included fully in-person and fully remote processes. Reasons for declining enrollment were collected among eligible patients who declined to participate but agreed to answer a short follow-up question. Qualitative data were analyzed using directed content analysis. Enrollment rates were assessed using simple, descriptive statistics.

Results: N = 417 COVID-19 positive inpatients were screened and 53/162 eligible patients enrolled. Enrollment varied across study sites and by study period. Prior to identification of effective treatment, the enrollment rate was 10/11 (91%) versus 43/144 (30%) during the later period of the study. N = 85/102 patients who did not enroll answered the follow-up question. The most commonly reported responses were: concerns about the study drug and participation in clinical research in general, comorbidity concerns, competing priorities, external factors, and external advice and influence from family members and clinicians.

Conclusions: Identifying reasons behind declining to enroll may help investigators develop strategies to increase research participation.

Keywords: COVID-19; Clinical trial; Clinical trial participation; Enrollment rates; IL-6 receptor inhibitor; Recruitment rates; Therapeutics trial.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Published by Elsevier Inc.

References

    1. COVID-19 Map Johns Hopkins Coronavirus Resource Center. Accessed April 13, 2022.
    1. Le R.Q., Li L., Yuan W., et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943–947. doi: 10.1634/theoncologist.2018-0028.
    1. Branch-Elliman W., Ferguson R., Doros G., et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. De Socio GV, ed. PLoS One. 2022;17(2) doi: 10.1371/journal.pone.0263591. e0263591.
    1. Bugin K., Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat. Rev. Drug Discov. 2021;20(4):254–255. doi: 10.1038/d41573-021-00037-3.
    1. Davis M.M., Clark S.J., Butchart A.T., Singer D.C., Shanley T.P., Gipson D.S. Public participation in, and awareness about, medical research opportunities in the era of clinical and translational research: awareness about medical research in the era of clinical and translational research. Clin Transl Sci. 2013;6(2):88–93. doi: 10.1111/cts.12019.
    1. Detoc M., Launay O., Dualé C., et al. Barriers and motivations for participation in preventive vaccine clinical trials: experience of 5 clinical research sites. Vaccine. 2019;37(44):6633–6639. doi: 10.1016/j.vaccine.2019.09.048.
    1. van den Bogert C.A., Souverein P.C., Brekelmans C.T.M., et al. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands. J. Clin. Epidemiol. 2017;88:140–147. doi: 10.1016/j.jclinepi.2017.05.001.
    1. Collins C.L., Malvar J., Hamilton A.S., Deapen D.M., Freyer D.R. Case-linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Institute-designated comprehensive cancer center: clinical trial enrollment among AYAs. Cancer. 2015;121(24):4398–4406. doi: 10.1002/cncr.29669.
    1. Scharff Darcell P., Mathews Katherine J., Jackson Pamela, Hoffsuemmer Jonathan, Martin Emeobong, Edwards Dorothy. More than Tuskegee: understanding mistrust about research participation. J. Health Care Poor Underserved. 2010;21(3):879–897. doi: 10.1353/hpu.0.0323.
    1. Scanlon J.K., Wofford L., Fair A., Philippi D. Predictors of participation in clinical research. Nurs. Res. 2021;70(4):289–297. doi: 10.1097/NNR.0000000000000513.
    1. DeSantis C.E., Siegel R.L., Sauer A.G., et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities: Cancer statistics for African Americans, 2016. CA Cancer J. Clin. 2016;66(4):290–308. doi: 10.3322/caac.21340.
    1. Fogel D.B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–164. doi: 10.1016/j.conctc.2018.08.001.
    1. Ramsey A.T., Proctor E.K., Chambers D.A., et al. Designing for accelerated translation (DART) of emerging innovations in health. J Clin Transl Sci. 2019;3(2–3):53–58. doi: 10.1017/cts.2019.386.
    1. Mitchell E.J., Ahmed K., Breeman S., et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020;21(1):784. doi: 10.1186/s13063-020-04711-6.
    1. Woods P., Flynn M., Monach P., et al. Implementation of documented and written informed consent for clinical trials of communicable diseases: lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. Contemp Clin Trials Commun. 2021;23 doi: 10.1016/j.conctc.2021.100804.
    1. The National Institutes of Health COVID-19 Treatment Guidelines Panel Provides Recommendations for Dexamethasone in Patients with COVID-19. National Institutes of Health; 2020. Accessed May 24, 2022.
    1. Coronavirus Disease 2019 (COVID-19 Treatment Guidelines National Institutes of Health. 2020. Accessed May 24, 2022.
    1. Hsieh H.F., Shannon S.E. Three approaches to qualitative content analysis. Qual. Health Res. 2005;15(9):1277–1288. doi: 10.1177/1049732305276687.
    1. La J., Fillmore N., Do N., Brophy M., Monach P., Branch-Elliman W. 2022. Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation. In Review.
    1. Monach P.A., Branch-Elliman W. Reconsidering ‘minimal risk’ to expand the repertoire of trials with waiver of informed consent for research. BMJ Open. 2021;11(9) doi: 10.1136/bmjopen-2020-048534.
    1. Nipp R.D., Hong K., Paskett E.D. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–114. doi: 10.1200/EDBK_243729.
    1. Sabesan S., Zalcberg J. In: Clinical Trials in Vulnerable Populations. Prostran M., editor. InTech; 2018. Access to clinical trials closer to home using tele-health.
    1. Sedrak M.S., Freedman R.A., Cohen H.J., et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J. Clin. 2021;71(1):78–92. doi: 10.3322/caac.21638.
    1. Hu K., Tardif J., Huber M., et al. Chasing the storm: recruiting non-hospitalized patients for a multi-site randomized controlled trial in the United States during the COVID-19 pandemic. Clin Transl Sci. 2022;15(4):831–837. doi: 10.1111/cts.13211.
    1. Abdelhafiz A.S., Abd ElHafeez S., Khalil M.A., et al. Factors influencing participation in COVID-19 clinical trials: A Multi-National Study. Front Med. 2021;8 doi: 10.3389/fmed.2021.608959.
    1. Mahmud A., Zalay O., Springer A., Arts K., Eisenhauer E. Barriers to participation in clinical trials: a physician survey. Curr. Oncol. 2018;25(2):119–125. doi: 10.3747/co.25.3857.
    1. Javid S.H., Unger J.M., Gralow J.R., et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast Cancer clinical trials (SWOG S0316) Oncologist. 2012;17(9):1180–1190. doi: 10.1634/theoncologist.2011-0384.
    1. Knowlson C., Torgerson D.J. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. F1000Research. 2020;9:1017. doi: 10.12688/f1000research.25842.2.
    1. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape. Accessed April 14, 2022.
    1. Jones W.S., Mulder H., Wruck L.M., et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N. Engl. J. Med. 2021;384(21):1981–1990. doi: 10.1056/NEJMoa2102137.
    1. Baigent C. Pragmatic trials — need for ADAPTABLE design. N. Engl. J. Med. 2021;384(21):2065–2066. doi: 10.1056/NEJMe2106430.
    1. Awad E., Paladugu R., Jones N., et al. Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity. Gynecol. Oncol. 2020;157(3):729–732. doi: 10.1016/j.ygyno.2020.03.002.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다